Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30398277 | 1.00 | DYRK1A (0.61) | DYRK1ADYRK1BCCNT1GSK3BCDK9 | |
| SCHEMBL30400138 | 0.84 | DYRK1A (0.78) | DYRK1ACCNT1GSK3BCDK9 | |
| SCHEMBL26174570 | 0.84 | DYRK1A (0.78) | DYRK1ACCNT1GSK3BCDK9 | |
| SCHEMBL26174568 | 0.82 | DYRK1A (0.65) | DYRK1ADYRK1BCCNT1GSK3BCDK9 | |
| SCHEMBL30399958 | 0.80 | DYRK1A (0.76) | DYRK1ADYRK1B | |
| SCHEMBL26174569 | 0.80 | DYRK1A (0.76) | DYRK1ADYRK1B | |
| SCHEMBL30399944 | 0.80 | EGFR (0.49) | — | |
| SCHEMBL26176355 | 0.80 | EGFR (0.49) | — | |
| SCHEMBL26174559 | 0.78 | DYRK1A (0.59) | DYRK1ADYRK1BCCNT1CDK9TDO2 | |
| SCHEMBL29283891 | 0.76 | DYRK1A (1.00) | DYRK1ACCNT1GSK3BCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | DYRK1A 1/4885DYRK1B 2/4885CCNT1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.